Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
250 mg capsule, 250 mg tablets · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | 500 mg LX1033, capsules administered two times per day orally |
| Treatment B | EXPERIMENTAL | 500 mg LX1033, tablets administered two times per day orally |
| Name | Type | Description |
|---|---|---|
| 250 mg capsule | DRUG | Two 250 mg capsules will be administered for 500 mg dose |
| 250 mg tablets | DRUG | Two 250 mg tablets will be administered for a 500 mg dose |
Inclusion Criteria: * Adult subjects age 18 to 55 years * Vital signs acceptable at Screening * Body mass index (BMI) between 18 and 35 kg/m\^2 at Screening * Considered to be in good health, as determined by the Investigator * Normal ECG findings * Negative urine screen for drugs of abuse and nega...
Top 3 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 3 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
LX1033 is an investigational drug being studied for the treatment of Irritable Bowel Syndrome. It is currently in Phase 1 clinical development and has been evaluated in a completed clinical trial involving healthy volunteers.
LX1033 is being developed by Lexicon Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol LXRX. The company is conducting clinical research on this investigational drug for gastrointestinal conditions.
LX1033 is in Phase 1 clinical development. A Phase 1 study of the drug has been completed, and it remains an investigational agent that has not yet been approved by regulatory authorities.
LX1033 has been studied in a completed Phase 1 clinical trial registered as NCT01411800. This open-label study evaluated two formulations of LX1033 in 28 healthy human subjects in the United States, with participants aged 18 years and older.